是时候改变2型糖尿病治疗模式了吗?不!二甲双胍应继续作为2型糖尿病的基础治疗。
本文为观点对比文章,讨论2型糖尿病一线治疗是否应从二甲双胍改为GLP-1受体激动剂。Inzucchi博士基于医学界广泛经验及该药已证实的疗效、安全性、低成本和心血管获益,认为二甲双胍应继续作为所有无禁忌证2型糖尿病患者的「基础治疗」。
要点
- 多数指南(包括美国糖尿病协会/欧洲糖尿病研究协会及国际糖尿病联盟)建议在饮食和运动后使用二甲双胍作为一线治疗。
- 该推荐基于过去30年积累的大量证据,也基于二甲双胍的可负担性和耐受性等临床理由。
- Inzucchi博士认为,基于广泛经验及疗效、安全性、低成本和心血管获益,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的基础治疗。
核心结论
- Inzucchi博士认为,基于医学界广泛经验及二甲双胍已证实的疗效、安全性、低成本和心血管获益,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的「基础治疗」。
研究设计与样本
- 本文为观点对比文章,就2型糖尿病一线治疗是否应从二甲双胍改为GLP-1受体激动剂展开讨论。
主要发现
- Abdul-Ghani与DeFronzo博士在前述观点文章中主张,基于纠正高血糖潜在病理生理异常的治疗策略应优先,需将一线治疗推荐从二甲双胍改为GLP-1受体激动剂。
- Inzucchi博士在反驳文章中指出,基于医学界广泛经验及该药已证实的疗效、安全性、低成本和心血管获益,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的基础治疗。
关键数值与推荐
- 美国糖尿病协会/欧洲糖尿病研究协会及国际糖尿病联盟等多数治疗指南建议,在饮食和运动后使用二甲双胍作为一线治疗。
- 该推荐基于过去30年积累的大量证据,并得到二甲双胍可负担性和耐受性等临床理由的支持。
- 二甲双胍是美国最常用的口服降糖药。
临床怎么用
- Inzucchi博士认为,二甲双胍应继续作为所有无禁忌证2型糖尿病患者的基础治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most treatment guidelines, including those from the American Diabetes Association/European Association for the Study of Diabetes and the International Diabetes Federation, suggest metformin be used as the first-line therapy after diet and exercise. This recommendation is based on the considerable body of evidence that has accumulated over the last 30 years, but it is also supported on clinical grounds based on metformin's affordability and tolerability. As such, metformin is the most commonly used oral antihyperglycemic agent in the U.S. However, based on the release of newer agents over the recent past, some have suggested that the modern approach to disease management should be based upon identification of its etiology and correcting the underlying biological disturbances. That is, we should use interventions that normalize or at least ameliorate the recognized derangements in physiology that drive the clinical manifestation of disease, in this circumstance, hyperglycemia. Thus, it is argued that therapeutic interventions that target glycemia but do not correct the underlying pathogenic disturbances are unlikely to result in a sustained benefit on the disease process. In our field, there is an evolving debate regarding the suggested first step in diabetes management and a call for a new paradigm. Given the current controversy, we provide a Point-Counterpoint debate on this issue. In the point narrative that precedes the counterpoint narrative below, Drs. Abdul-Ghani and DeFronzo provide their argument that a treatment approach for type 2 diabetes based upon correcting the underlying pathophysiological abnormalities responsible for the development of hyperglycemia provides the best therapeutic strategy. Such an approach requires a change in the recommendation for first-line therapy from metformin to a GLP-1 receptor agonist. In the counterpoint narrative below, Dr. Inzucchi argues that based on the medical community's extensive experience and the drug's demonstrated efficacy, safety, low cost, and cardiovascular benefits, metformin should remain the "foundation therapy" for all patients with type 2 diabetes, barring contraindications.-William T. CefaluChief Scientific, Medical & Mission Officer, American Diabetes Association.
引用
- Inzucchi SE. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. Diabetes Care. 2017. PMID: 28733378. doi:10.2337/dc16-2372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。